Bilateral, sequential orbital inflammatory syndrome associated with ruxolitinib.
Sign Up to like & getrecommendations! Published in 2022 at "Orbit"
DOI: 10.1080/01676830.2022.2109177
Abstract: Ruxolitinib is an oral Janus associated kinase (JAK) inhibitor commonly used in the treatment of primary myelofibrosis. We describe a case of an 86-year-old woman on ruxolitinib for primary myelofibrosis who presented with a three-day… read more here.
Keywords: ruxolitinib; bilateral sequential; inflammatory syndrome; orbital inflammatory ... See more keywords